John J. Cheney

Member vCard


  • Boston University School of Law (JD, 1989)
  • Harvard University (BA, 1982)

Bar Admissions

  • Massachusetts

John’s practice includes the representation of a range of start-up and late-stage biotechnology and pharmaceutical companies, both private and public. He has extensive experience in venture capital financing, private placements, mergers and acquisitions, public offerings, and general corporate matters. In addition, he specializes in technology licensing transactions and in the structuring and negotiation of sponsored research and other collaborations, strategic alliances, and joint ventures.

John has represented a number of biotechnology clients in their early- and late-stage financing transactions. Recently, he negotiated and closed a $75 million equity financing transaction, which was the highest-grossing, self-managed private placement ever consummated within the biotechnology industry.

John has also been involved in a number of complex collaboration and joint venture transactions with biotechnology and pharmaceutical companies, including a collaboration/co-development transaction valued at approximately $1.5 billion, which remains the largest collaboration (in terms of aggregate value) between a biotechnology and pharmaceutical company completed to date.

In addition, John has served as both company counsel and underwriter’s counsel on initial public offerings, follow-on offerings, and PIPE financing transactions involving a number of biotechnology and medical device companies.

John spends a significant part of his practice representing international biotechnology clients in all aspects of their business. He works with start-up and leading biotechnology companies, both in Germany and Israel. He also participated in the drafting and negotiation of the key technology transfer agreements executed in connection with the Estonian Genome Project.

Before joining Mintz Levin, John was an associate at Palmer & Dodge, LLP and Sullivan & Worcester, LLP, where he represented a variety of biotechnology and pharmaceutical companies. Before law school, he was involved in a three-year research project at Dana-Farber Cancer Institute, focused primarily in the areas of lupus and arthritis, under Dr. Stuart Schlossman.